T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting

Recent studies have highlighted a major role for cancer-associated fibroblasts (CAFs) in promoting immunotherapy resistance by excluding T cells from tumours. Recently, we showed that CAFs can be effectively targeted by inhibiting the enzyme NOX4; this ‘normalises’ CAFs and overcomes immunotherapy r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanley, Christopher J., Thomas, Gareth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591574/
https://www.ncbi.nlm.nih.gov/pubmed/32830198
http://dx.doi.org/10.1038/s41416-020-1020-6
_version_ 1783601024942997504
author Hanley, Christopher J.
Thomas, Gareth J.
author_facet Hanley, Christopher J.
Thomas, Gareth J.
author_sort Hanley, Christopher J.
collection PubMed
description Recent studies have highlighted a major role for cancer-associated fibroblasts (CAFs) in promoting immunotherapy resistance by excluding T cells from tumours. Recently, we showed that CAFs can be effectively targeted by inhibiting the enzyme NOX4; this ‘normalises’ CAFs and overcomes immunotherapy resistance. Here we discuss our study and other strategies for CAF targeting.
format Online
Article
Text
id pubmed-7591574
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75915742021-08-24 T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting Hanley, Christopher J. Thomas, Gareth J. Br J Cancer Comment Recent studies have highlighted a major role for cancer-associated fibroblasts (CAFs) in promoting immunotherapy resistance by excluding T cells from tumours. Recently, we showed that CAFs can be effectively targeted by inhibiting the enzyme NOX4; this ‘normalises’ CAFs and overcomes immunotherapy resistance. Here we discuss our study and other strategies for CAF targeting. Nature Publishing Group UK 2020-08-24 2020-10-27 /pmc/articles/PMC7591574/ /pubmed/32830198 http://dx.doi.org/10.1038/s41416-020-1020-6 Text en © Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Comment
Hanley, Christopher J.
Thomas, Gareth J.
T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
title T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
title_full T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
title_fullStr T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
title_full_unstemmed T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
title_short T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
title_sort t-cell tumour exclusion and immunotherapy resistance: a role for caf targeting
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591574/
https://www.ncbi.nlm.nih.gov/pubmed/32830198
http://dx.doi.org/10.1038/s41416-020-1020-6
work_keys_str_mv AT hanleychristopherj tcelltumourexclusionandimmunotherapyresistancearoleforcaftargeting
AT thomasgarethj tcelltumourexclusionandimmunotherapyresistancearoleforcaftargeting

Ejemplares similares